FDA

Last month, the CDC and FDA investigated a multi-state outbreak of infections caused by Burkholderia cepacia complex. B. cepacia complex is normally not a pathogen in the ambulatory setting, but [...]

Brintellix (vortioxetine) is a relatively new serotonergic antidepressant, approved to treat major depressive disorder in September 2013. In recent FDA MedWatch news, there were numerous reports [...]

The FDA has withdrawn approvals for the use of niacin or fenofibrate in combination with statins for the treatment of high cholesterol. The FDA also withdrew approval of the indications related [...]

SGLT2 inhibitors Last year, the FDA released a drug safety communication, which cautioned the use of SGLT2 inhibitors, due to case reports of ketoacidosis in patients who were being treated with [...]

The FDA granted accelerated approval of Praxbind (idarucizumab) on October 16, 2015 for use as a specific reversal agent of the anticoagulant effects of Pradaxa (dabigatran etexilate) during [...]

The U.S. Food and Drug Administration (FDA) approved another anti-clotting drug Savaysa (edoxaban) in January 2015 for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). [...]